129 related articles for article (PubMed ID: 16113755)
1. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
[TBL] [Abstract][Full Text] [Related]
2. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
3. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
5. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Casslén B; Bossmar T; Lecander I; Astedt B
Eur J Cancer; 1994; 30A(9):1302-9. PubMed ID: 7999418
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts.
Xiao Y; Bunn CL; Bartold PM
J Periodontal Res; 1998 Jan; 33(1):17-26. PubMed ID: 9524317
[TBL] [Abstract][Full Text] [Related]
8. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
9. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
12. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
13. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
Borstnar S; Vrhovec I; Svetic B; Cufer T
Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
18. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis.
Kinnby B; Matsson L; Lecander I
Scand J Dent Res; 1994 Dec; 102(6):334-41. PubMed ID: 7871356
[TBL] [Abstract][Full Text] [Related]
19. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Ronday HK; Smits HH; Van Muijen GN; Pruszczynski MS; Dolhain RJ; Van Langelaan EJ; Breedveld FC; Verheijen JH
Br J Rheumatol; 1996 May; 35(5):416-23. PubMed ID: 8646430
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of plasminogen activators in human gingival crevicular fluid.
Brown JM; Watanabe K; Cohen RL; Chambers DA
Arch Oral Biol; 1995 Sep; 40(9):839-45. PubMed ID: 8651888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
